...
首页> 外文期刊>Journal of cataract and refractive surgery >Corneal endothelial cell injury induced by mitomycin-C in photorefractive keratectomy: nonrandomized controlled trial.
【24h】

Corneal endothelial cell injury induced by mitomycin-C in photorefractive keratectomy: nonrandomized controlled trial.

机译:丝裂霉素-C在光折射性角膜切除术中诱导的角膜内皮细胞损伤:非随机对照试验。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To evaluate the effect of intraoperative use of mitomycin-C (MMC) on the corneal endothelium during excimer laser photorefractive keratectomy (PRK). SETTING: Vanak Eye Surgery Center, Tehran, Iran. METHODS: This nonrandomized trial comprised 81 patients (162 eyes) with bilateral low to moderate myopia and adequate corneal thickness to allow PRK (estimated postoperative residual stromal thickness >350 microm without considering epithelial thickness). The indication for intraoperative application of MMC 0.02% (0.2 mg/mL) was an ablation depth of 75 microm or more. Patients were divided into 3 groups: bilateral (both eyes treated with MMC), unilateral (only 1 eye treated with MMC), and untreated (no eye treated with MMC). Visual acuity, refraction, endothelial cell density (ECD), and corneal thickness were measured preoperatively as well as 1 week and 1, 3, and 6 months postoperatively. RESULTS: Overall, 76 eyes were treated with MMC. Eyes treated with MMC and untreated eyes were comparable in postoperative visual acuity and refraction. Preoperative to postoperative changes in ECD were statistically significantly greater in the treated eyes (-14.8%) than in untreated eyes (-5.1%) 6 months after PRK (P<.001). Longer MMC contact time (P<.001) and male sex (P= .04) were the only factors independently associated with greater endothelial cell loss. CONCLUSIONS: The prophylactic use of diluted intraoperative MMC 0.02% solution caused corneal endothelial cell loss. The rate of cell loss was correlated with the duration of MMC exposure.
机译:目的:评估在准分子激光屈光性角膜切除术(PRK)期间术中使用丝裂霉素-C(MMC)对角膜内皮的影响。地点:伊朗德黑兰Vanak眼外科中心。方法:该非随机试验包括81例(162眼)双侧低至中度近视且角膜厚度足以允许PRK(估计的术后残余基质厚度> 350微米,不考虑上皮厚度)的患者。术中应用0.02%(0.2 mg / mL)MMC的适应症是消融深度为75微米或以上。将患者分为三组:双侧(两只眼睛都接受MMC治疗),单侧(只有1只眼睛接受MMC治疗)和未接受治疗(没有眼睛接受MMC治疗)。术前以及术后1周,1、3和6个月测量视力,屈光度,内皮细胞密度(ECD)和角膜厚度。结果:总体上,MMC治疗了76只眼。 MMC治疗的眼睛和未经治疗的眼睛在术后视力和屈光度方面具有可比性。 PRK后6个月,经治疗的眼睛的术前至术后ECD变化在统计学上显着大于未治疗的眼睛(-5.1%)(-14.8%)(P <.001)。较长的MMC接触时间(P <.001)和男性(P = .04)是与更大的内皮细胞损失独立相关的唯一因素。结论:术中使用稀释度为0.02%的MMC稀释液可预防角膜内皮细胞损失。细胞丢失率与MMC暴露持续时间相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号